The Berlin-based biotechnology company MOLOGEN announced today that it has entered an agreement with “China Import-Marketing und Promotion GmbH”, Cologne (C.I.P.) for licensing and distributing its innovative cell-based gene therapy in Asia.
The Berlin-based biotechnology company MOLOGEN announced today that it has entered an agreement with “China Import-Marketing und Promotion GmbH”, Cologne (C.I.P.) for licensing and distributing its innovative cell-based gene therapy in Asia.
